GLP-1 Medications for Sleep Apnea: The SURMOUNT-OSA Evidence

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited · Author: FormBlends Editorial

Key Takeaways

• Tirzepatide (Zepbound) received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, based on the SURMOUNT-OSA program
• SURMOUNT-OSA showed AHI reduction of ~27-30 events per hour at 52 weeks, alongside ~18-20% weight loss
• Many patients moved from moderate or severe OSA to mild or no OSA on objective sleep studies; some no longer required CPAP
• Coverage for tirzepatide under the OSA indication began rolling into commercial plans during 2025; Medicare coverage has been slower
• Semaglutide is not FDA-approved for OSA, but produces similar weight-mediated improvements through its obesity indication

Direct answer

Tirzepatide is the first GLP-1 medication with an FDA-approved indication for sleep apnea, granted in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. The SURMOUNT-OSA trial program demonstrated AHI reduction of approximately 27-30 events per hour at 52 weeks, alongside substantial weight loss. The benefit is mostly weight-mediated; reducing body weight by 18-20% reduces airway fat deposition and collapsibility. Many patients moved out of the moderate or severe OSA range. CPAP is often still needed during titration and may continue indefinitely for patients with residual OSA. Other GLP-1 medications do not yet hold OSA indications but likely produce similar effects via weight loss.

Table of contents

1. The OSA-obesity link in plain terms
2. SURMOUNT-OSA trial design and results
3. The December 2024 FDA approval and what it actually covers
4. How GLP-1 reduces OSA: mechanism
5. GLP-1 versus CPAP: not really an either/or
6. The repeat sleep study question
7. Semaglutide off-label for OSA
8. Other GLP-1 medications and the OSA case
9. Coverage outlook 2025-2026
10. Where the evidence is still soft
11. Decision framework
12. FAQ
13. Sources

The OSA-obesity link in plain terms

Obstructive sleep apnea (OSA) and obesity are closely intertwined. Estimates suggest 60-70% of adults with moderate-to-severe OSA have BMI in the overweight or obese range. The relationship is bidirectional: obesity causes airway narrowing and increases OSA risk; OSA disrupts sleep, which worsens metabolic regulation and promotes further weight gain.

Anatomic and physiologic contributions of obesity to OSA:

• Fat deposition around the pharynx narrows the airway
• Reduced lung volumes in obesity decrease tracheal traction on the upper airway, making it more collapsible
• Abdominal obesity reduces functional residual capacity
• Increased leptin and inflammatory mediators may alter chemoreceptor sensitivity
• Higher neck circumference correlates with OSA severity

Pre-GLP-1 evidence already showed that substantial weight loss (typically 10%+) reduces OSA severity. The Sleep AHEAD study (Foster et al., 2009) showed lifestyle-based weight loss in patients with type 2 diabetes and OSA reduced AHI by 9-10 events per hour, with corresponding improvement in symptoms.

The question GLP-1 medications answered was whether pharmacotherapy-driven weight loss would produce similar or larger AHI reductions and whether the regulatory bar could be cleared for a specific OSA indication.

SURMOUNT-OSA trial design and results

SURMOUNT-OSA comprised two phase 3 studies enrolling 469 adults with obesity (BMI 30+) and moderate-to-severe OSA (AHI 15+). Malhotra et al. published results in NEJM 2024.

Study 1: participants not using positive airway pressure (PAP) therapy
Study 2: participants on stable PAP therapy

Both studies tested tirzepatide titrated to 10 mg or 15 mg weekly versus placebo over 52 weeks.

Approximate results from the two studies pooled:

Outcome at 52 weeks	Tirzepatide	Placebo
AHI reduction (events/hour)	~27-30	~4-6
Body weight change	~ -18-20%	~ -1-2%
Patients reaching AHI < 5 OR >50% reduction	~50-60%	~12-15%
Resolution to AHI < 5 events/hour	~40-45%	~12-15%
Improvement in sleep apnea-specific quality of life scores	Significant	Minimal

Some patients with severe OSA at baseline (AHI 30+) moved to mild OSA (AHI 5-15) or normalized completely. Others remained in the moderate-to-severe range despite substantial improvement. The magnitude of AHI reduction correlated with the magnitude of weight loss.

Both studies met their primary endpoint (change in AHI) with statistical significance. The two-study design (with and without PAP) provided coverage for the most common clinical situations.

The December 2024 FDA approval and what it actually covers

The FDA approved tirzepatide (Zepbound brand) for moderate-to-severe OSA in adults with obesity on December 20, 2024. The approval expanded the existing Zepbound obesity indication to include OSA as a specifically named condition.

The label specifies:

• Adults with moderate-to-severe obstructive sleep apnea
• Obesity (BMI 30+)
• Use alongside reduced-calorie diet and increased physical activity
• Same dose titration as the obesity indication (2.5 → 15 mg weekly)

The OSA indication is meaningful for several reasons:

• It expands the population for whom Zepbound coverage is justified at higher BMI thresholds, even when other comorbidities are absent
• It creates a coverage path through OSA diagnosis codes that bypasses obesity-alone restrictions in some plans
• It positions tirzepatide as a treatment for OSA itself, not just for its underlying obesity
• It supports cardiovascular and cardiometabolic risk reduction by addressing OSA, which independently elevates cardiovascular risk

Other tirzepatide brand (Mounjaro, indicated for type 2 diabetes) does not carry the OSA indication. The same molecule, but the regulatory labels are separate.

How GLP-1 reduces OSA: mechanism

The dominant mechanism is weight loss. Fat reduction around the upper airway decreases anatomic crowding. Reduced abdominal fat increases lung volumes, which increases tracheal traction on the upper airway and reduces collapsibility.

Approximate contribution attribution from the trial data:

• ~70-80% of AHI improvement appears weight-mediated based on correlation analyses
• The remaining 20-30% is unaccounted for by weight alone; possible contributions from systemic inflammation reduction, glucose normalization, and direct effects on respiratory drive

The mechanism question matters because if GLP-1 has weight-independent effects on OSA, low-dose protocols or non-obesity uses might preserve some benefit. The available evidence does not yet support this, but it has not been ruled out.

GLP-1 versus CPAP: not really an either/or

Continuous positive airway pressure (CPAP) and related PAP therapies treat the airway directly. They keep the airway open mechanically. They work immediately, do not require weight loss, and are highly effective when used consistently.

The downsides of CPAP are real:

• Adherence is challenging; long-term consistent use rates are 50-70%
• Mask discomfort, claustrophobia, dry mouth
• Travel and intimacy disruption
• Does not address the underlying obesity

GLP-1 medications treat OSA by addressing the underlying obesity. They take months to produce meaningful AHI reduction. They do not work immediately. But they also address weight, cardiovascular risk, glucose metabolism, and other comorbidities simultaneously.

The practical clinical reality is usually both, sequentially:

1. Diagnose OSA with sleep study
2. Start CPAP for symptomatic relief and immediate cardiovascular risk reduction
3. Start GLP-1 medication for weight and OSA modification
4. At 12-18 months, reassess with repeat sleep study
5. If AHI is below 5 (or the threshold for treatment cessation), consider stopping CPAP
6. If AHI remains elevated, continue CPAP alongside ongoing weight management

Some patients become CPAP-free after substantial weight loss. Others continue both indefinitely. The decision is made on objective sleep study data, not patient preference alone.

The repeat sleep study question

The OSA diagnosis is anchored to objective data (polysomnography or home sleep test). Treatment decisions follow the same logic: stopping CPAP requires evidence the OSA is resolved.

Best practice in 2026, broadly:

• Repeat sleep study after meaningful weight loss (typically 10%+ from baseline)
• Document AHI without CPAP
• If AHI is below 5 and symptoms resolved, CPAP can be stopped with monitoring
• If AHI is in mild range (5-15) and symptoms minimal, decision is patient-clinician individualized
• If AHI remains moderate or severe, CPAP continues

Repeat sleep studies are not always covered routinely; some plans require recent (within 6 months) symptom assessment plus weight documentation to justify repeat testing.

Semaglutide off-label for OSA

Semaglutide does not hold an FDA OSA indication. Clinical trials of semaglutide in OSA-specific populations are limited, though substantial OSA improvement has been observed in obesity trials that tracked OSA as a secondary outcome.

For patients with OSA and obesity who are using semaglutide (Wegovy, Ozempic, or compounded), the OSA benefit accrues alongside the obesity treatment. Insurance coverage flows through the obesity indication (Wegovy under BMI 30+ or 27+ with comorbidity, where OSA can serve as the comorbidity).

The cross-medication implication: choose the medication based on coverage, tolerability, and individual factors. Tirzepatide has the regulatory advantage of the OSA-specific indication. Semaglutide accomplishes similar goals via the obesity path.

Other GLP-1 medications and the OSA case

Other agents in or near the OSA conversation:

Medication	OSA-specific evidence	FDA OSA status
Tirzepatide (Zepbound)	SURMOUNT-OSA positive	Approved Dec 2024
Semaglutide (Wegovy)	OSA improvements as secondary outcomes in obesity trials	Not approved for OSA
Liraglutide (Saxenda)	Smaller trials showing modest AHI reduction	Not approved for OSA
Retatrutide	Investigational; phase 3 obesity trials may include OSA secondary outcomes	Not approved for any indication
Survodutide	Not specifically studied for OSA	Not approved

Future approvals could add semaglutide or retatrutide to the OSA-approved list if sponsors pursue dedicated trials. The market incentive exists; OSA is a large indication with growing diagnosis rates.

Coverage outlook 2025-2026

Following the December 2024 Zepbound OSA approval, commercial plan coverage updates began rolling out in 2025. The pattern as of May 2026:

• Most commercial plans added OSA-specific Zepbound coverage during 2025 formulary updates
• Prior authorization typically requires documented OSA diagnosis (AHI 15+), BMI 30+, and sometimes a documented PAP trial or intolerance
• Medicare Part D coverage has been slower; some plans cover for OSA but many do not, citing CMS's broader hesitation to cover weight-loss medications
• Medicaid coverage varies by state; some states added Zepbound for OSA, others have not
• OSA-specific coverage often runs parallel to existing obesity coverage; patients with both indications may have multiple coverage paths

A separate FormBlends article (AEO-3585, AEO-3586) covers the Zepbound-for-OSA insurance and Medicare-specific questions in more depth.

Where the evidence is still soft

Gap 1: Long-term durability. SURMOUNT-OSA was 52 weeks. Whether the AHI reduction persists at 3, 5, or 10 years on continuous tirzepatide is unknown. Whether benefit persists if patients stop the medication is also unknown.

Gap 2: OSA without obesity. Some patients have OSA at lower BMI. SURMOUNT-OSA enrolled BMI 30+. The case for tirzepatide in lean OSA is not yet established.

Gap 3: Central sleep apnea. SURMOUNT-OSA targeted obstructive sleep apnea. Central sleep apnea (where the brain transiently fails to signal breathing) has different mechanisms and is not addressed by tirzepatide trial data.

Gap 4: Cardiovascular outcome data specific to OSA treatment. CPAP reduces blood pressure but has mixed cardiovascular outcome data. Whether tirzepatide-driven OSA improvement translates to long-term CV benefit beyond the SELECT-style benefits of weight loss is not yet established.

Gap 5: Pediatric OSA. Pediatric obesity GLP-1 indications now exist (semaglutide for adolescent obesity), but pediatric OSA-specific data are limited.

Decision framework

If you have moderate-to-severe OSA and obesity (BMI 30+): Tirzepatide is FDA-approved for your indication. Discuss with your clinician. CPAP is usually started or continued during weight loss; reassessment at 12-18 months determines whether you can stop CPAP.

If you have OSA and BMI 27-30: Tirzepatide for OSA at this BMI tier is not directly on-label. Obesity-with-comorbidity coverage (BMI 27+ with OSA as the comorbidity) may apply for Wegovy or Zepbound. Insurance specifics vary.

If you use CPAP and want to stop: Discuss with your sleep medicine clinician. Stopping CPAP requires repeat sleep study documenting AHI below treatment threshold. Premature CPAP discontinuation carries real cardiovascular and accident risk.

If you have OSA and prefer not to use CPAP: GLP-1 medications are not a CPAP substitute in the short term. They take months to work. Most patients use both during titration.

If you have OSA and diabetes: Tirzepatide (under Mounjaro brand) is on-label for diabetes. The OSA benefit accrues alongside diabetes treatment. Insurance coverage runs through the diabetes pathway.

If you have central sleep apnea or mixed OSA-CSA: GLP-1 efficacy is not established for the central component. PAP devices (BiPAP, ASV) remain the primary treatment.

Retatrutide status for this question

For GLP-1 Medications for Sleep Apnea: The SURMOUNT-OSA Evidence, the starting point is regulatory status: retatrutide remains investigational as of May 2026 and is not FDA-approved. FormBlends does not sell, prescribe, dispense, or supply retatrutide; the legitimate access path is clinical-trial participation.

This page is education about the evidence and safety boundaries for glp1, for, sleep, apnea, evidence. It is not dosing, purchasing, mixing, or preparation guidance. If you need treatment now, ask a licensed clinician about approved options such as semaglutide or tirzepatide.

FAQ

Is GLP-1 medication FDA-approved for sleep apnea?

Tirzepatide (Zepbound) was approved for moderate-to-severe OSA in adults with obesity in December 2024. Other GLP-1 medications do not have OSA-specific approvals.

What did SURMOUNT-OSA show?

AHI reduction of approximately 27-30 events per hour at 52 weeks, with weight loss of 18-20%. Many patients moved from severe to mild or no OSA.

Does GLP-1 replace CPAP?

For many patients, no. Tirzepatide reduces OSA but may not eliminate it. Repeat sleep study confirms whether CPAP can be stopped.

How fast does it work?

Meaningful AHI reduction usually by 6 months. Largest changes accrue over 12-18 months. Symptoms (snoring, daytime fatigue) often improve earlier than AHI numbers fully normalize.

Is it just weight loss doing the work?

Mostly. ~70-80% of AHI improvement appears weight-mediated. Direct effects on inflammation or respiratory drive may contribute the remainder.

Will insurance cover Zepbound for OSA?

Commercial coverage expanded after the December 2024 FDA approval. Medicare and Medicaid lagged. Prior authorization typically requires AHI 15+, BMI 30+, and sometimes documented CPAP history.

What is AHI?

Apnea-hypopnea index, breathing events per hour during sleep. Mild OSA: 5-15. Moderate: 15-30. Severe: 30+. Treatment success often targets AHI below 5 or 50% reduction.

Can I use semaglutide for OSA?

Off-label, yes, with likely similar weight-mediated benefit. But not FDA-approved for OSA; coverage runs through obesity pathway only.

Does it help if I have mild OSA?

The trial enrolled moderate-to-severe (AHI 15+). For mild OSA (AHI 5-15) with significant symptoms, treatment decisions are individualized. Weight loss helps regardless.

Are there side effects specific to OSA use?

Standard GLP-1 side effect profile applies (nausea, GI). No OSA-specific safety signals emerged in SURMOUNT-OSA.

What about kids with OSA?

Adolescent obesity GLP-1 indications exist for some medications, but OSA-specific pediatric trials are limited. Discuss with a pediatric sleep specialist.

How do I get a repeat sleep study covered?

Document weight loss, symptom assessment, and the clinical question being asked (is CPAP still needed). Some plans require recent BMI and symptom check before authorizing repeat testing.

Related guides

• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• GLP-1 Medications for PCOS: What the Evidence Actually Shows
• GLP-1 Medications for MASH and Fatty Liver: The Evidence Map
• GLP-1 Medications and Alcohol Use Disorder: The Emerging Evidence
• GLP-1 Medications, Depression, and Anxiety: What the Evidence Shows
• GLP-1 Medications and Kidney Disease: FLOW Trial Evidence

Sources

1. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine. 2024.
2. FDA Drug Label. Zepbound (tirzepatide) Prescribing Information. Updated December 2024 to include OSA indication.
3. Foster GD et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes (Sleep AHEAD). Archives of Internal Medicine. 2009.
4. American Academy of Sleep Medicine. Clinical Practice Guideline for the Treatment of Adult Obstructive Sleep Apnea. 2019 update.
5. Peppard PE et al. Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology. 2013.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
8. Romero-Corral A et al. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010.
9. American Thoracic Society Statement on OSA in Obesity. 2023.
10. Yu J et al. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea. JAMA. 2017.
11. CMS Coverage Guidance. Sleep Apnea Diagnostic Testing. 2024-2025.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
13. Patil SP et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational content and connects patients with independent licensed providers. Sleep apnea diagnosis and management often require sleep medicine specialist involvement. This article is not a substitute for personalized clinical evaluation.

Compounded Medication Notice. Compounded tirzepatide and semaglutide are not FDA-approved and have not been specifically studied for OSA outside SURMOUNT-OSA (which used brand-name tirzepatide). Compounded medications are prepared by state-licensed 503A pharmacies pursuant to individual prescriptions and are not interchangeable with brand-name products.

Results Disclaimer. SURMOUNT-OSA results describe averages across the trial population. Individual response varies by baseline AHI, BMI, adherence, anatomic factors, and other variables. Stopping CPAP requires objective sleep study confirmation, not symptom improvement alone.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. CPAP and BiPAP are generic terms; specific device brand names belong to their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.